Bristol-Myers Squibb Co (BMY)
44.85
+0.15
(+0.34%)
USD |
NYSE |
Apr 26, 16:00
44.87
+0.02
(+0.04%)
After-Hours: 20:00
Bristol-Myers Squibb Cash from Financing (Quarterly): 14.64B for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.64B |
| December 31, 2023 | 967.00M |
| September 30, 2023 | -5.16B |
| June 30, 2023 | -2.173B |
| March 31, 2023 | -3.05B |
| December 31, 2022 | -3.246B |
| September 30, 2022 | -4.543B |
| June 30, 2022 | -3.52B |
| March 31, 2022 | -5.653B |
| December 31, 2021 | -3.967B |
| September 30, 2021 | -1.78B |
| June 30, 2021 | -3.182B |
| March 31, 2021 | -7.295B |
| December 31, 2020 | 3.483B |
| September 30, 2020 | -2.587B |
| June 30, 2020 | -993.00M |
| March 31, 2020 | -1.054B |
| December 31, 2019 | -7.677B |
| September 30, 2019 | -941.00M |
| June 30, 2019 | 18.27B |
| March 31, 2019 | -2.029B |
| December 31, 2018 | -578.00M |
| September 30, 2018 | -720.00M |
| June 30, 2018 | -1.015B |
| March 31, 2018 | -1.222B |
| Date | Value |
|---|---|
| December 31, 2017 | -1.352B |
| September 30, 2017 | -706.00M |
| June 30, 2017 | -1.006B |
| March 31, 2017 | -1.013B |
| December 31, 2016 | -605.00M |
| September 30, 2016 | -546.00M |
| June 30, 2016 | -552.00M |
| March 31, 2016 | -950.00M |
| December 31, 2015 | -1.359B |
| September 30, 2015 | -700.00M |
| June 30, 2015 | -883.00M |
| March 31, 2015 | -682.00M |
| December 31, 2014 | -231.00M |
| September 30, 2014 | -528.00M |
| June 30, 2014 | -486.00M |
| March 31, 2014 | -1.192B |
| December 31, 2013 | 711.00M |
| September 30, 2013 | -620.00M |
| June 30, 2013 | -1.115B |
| March 31, 2013 | -44.00M |
| December 31, 2012 | -958.00M |
| September 30, 2012 | -1.689B |
| June 30, 2012 | -850.00M |
| March 31, 2012 | -836.00M |
| December 31, 2011 | -754.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.677B
Minimum
Dec 2019
18.27B
Maximum
Jun 2019
-972.95M
Average
-2.818B
Median
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | 2.754B |
| Biogen Inc | -439.60M |
| Gilead Sciences Inc | -1.099B |
| Karuna Therapeutics Inc (DELISTED) | 19.87M |
| 2seventy bio Inc | 0.253M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.834B |
| Cash from Investing (Quarterly) | -19.62B |
| Free Cash Flow | 12.51B |
| Free Cash Flow Per Share (Quarterly) | 1.260 |
| Free Cash Flow to Equity (Quarterly) | -13.36B |
| Free Cash Flow to Firm (Quarterly) | 2.989B |
| Free Cash Flow Yield | 13.57% |